Heartburn Medication Recall 2019: Another Recall Issued For Ranitidine Tablets, Syrups Over Cancer Concerns

After several retailers pulled ranitidine heartburn medications from their shelves, Amneal Pharmaceuticals, LLC (AMRX) has issued a recall for several ranitidine tablets and syrups because they may contain a cancer-causing impurity.

The recall affects 150 and 300 mg ranitidine tablets and 15 mg/mL ranitidine syrups. The affected medication may have N-Nitrosodimethylamine (NDMA) in amounts that are above the levels set by the U.S. Food & Drug Administration (FDA). NDMA is a substance that could cause cancer.

The ranitidine medication was produced by Amneal and is used to treat stomach acid, including the prevention of ulcers and gastroesophageal reflux disease.

Consumers can identify the recalled medication by the NDC numbers located on the product label. The affected medication was distributed to wholesalers, distributors, retailers, and repackagers.

A full list of recalled medication can be viewed here.

Consumers who have the recalled ranitidine tablets or syrup should stop using the medication. They should contact Stericycle at 1-866-918-8768, Monday through Friday from 8 a.m. to 5 pm. EST for more information.

Adverse reactions to the affected medication can be reported to Amneal Drug Safety at 1-877-835-5472, Monday through Friday from 8 a.m. to 6 p.m. EST or by email at DrugSafety@amneal.com.

Amneal has not received any reports of adverse reactions due to the recalled medication. Individuals that experience problems from the affected ranitidine tablets or syrup should contact their healthcare provider.

Shares of Amneal stock were up 1.89% as of 9:19 a.m. EST on Wednesday.